Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NitroMed: Patience pays off

NitroMed Inc. has waited almost six years for validation of its contention that BiDil, a nitric oxide-donating compound, would show benefit in African-American patients with heart failure. The company was prepared to wait even longer. But that won't be necessary, as last week NTMD halted its Phase III A-HeFT trial after a Data Safety and Monitoring Board (DSMB) and Steering Committee determined it would be unethical to continue the placebo-controlled study based on the significant survival benefit seen in the treatment group.

The data, in combination with new research associating nitric oxide

Read the full 928 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE